Zydus Cadila receives tentative approval from USFDA to market Pimavanserin tablets

Ahmedabad: Zydus Cadila has received tentative approval from the USFDA to market Pimavanserin tablets in 10 mg capacity. The approved medicinal drug is a generic version of the Reference Listed Drug Nuplazid Tablets in the United States.

Pimavanserin is used to treat the symptoms of a certain mental or mood disorder, known as psychosis, that might occur with Parkinson's disease. It helps lessen symptoms such as hallucinations (seeing or hearing things that are not there) and delusions (false beliefs) commonly observed in patients of the disease.

The drug will be manufactured at the group’s formulation manufacturing facility SEZ in Ahmedabad. With this approval, Zydus group has now received 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.